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Introduction
Pain relief  after total knee arthroplasty continues to be a subject 
of  debate. Although there are a variety of  pharmacological thera-
pies, no ideal drug has been found to date [1, 2].
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly 
used for the treatment of  post-operative pain in order to reduce 
opioids administration and their adverse effects [3, 4].
Cyclooxygenase-2 (COX-2) specific inhibitors are advantageous 
over the previous generations of  NSAIDs in terms of  safety, 
since they have significantly less gastrotoxicity and no effects on 
platelet aggregation, important in the postoperative setting [5, 6].
Etoricoxib [7] belonging to the second class of  selective inhibitors 
of  COX-2, has a good absorption rate and a half-life of  22 hours 
that allows administration of  a single 120 mg tablet daily. Litera-
ture data show that its absorbtion is complete in about 24 minutes 
after administration [8] and its postoperative use as an analgetic 
was demonstrated to be efficient and safe. Rawal et al., used post-
operative etoricoxib 90 and 120 mg in patients undergoing TKA 
and found it superior to placebo and non-inferior to ibuprofen in 
reducing pain at rest and morphine consumption [9].
Rasmussen et al., used etoricoxib 120 mg daily on 228 patients 
with knee and hip arthroplasty and showed it provided analgesia 
similar to naproxen sodium 1100 mg at the first 24 hours after 
surgery and superior to placebo, with reduced opioid medication 
[10].
Lornoxicam [7] is a potent new NSAIDs oxicam derivative, which 
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exerts its analgesic effect via inhibition of  cyclooxygenase I and 
II and also by release of  endogenous dynorphins and beta‐en-
dorphins.
It is available for parenteral and enteral administration. It has a 
relatively rapid on set of  action compared to other oxicams and 
a shorter half-life (approximately 4 hours) that explains its im-
proved gastrointestinal safety profile [11, 12].
The aim of  this study was to demonstrate the analgesic efficacy 
and safety profile of  lornoxicam administered postoperatively af-
ter TKA performed under spinal anaesthesia versus etoricoxib.
Material and Method
Ethical approval of  the study was provided by the Ethics Com-
mittee of  the Orthopedics Hospital Foisor, Bucharest, Romania 
(Protocol ID AN-002-13). 
After obtaining the written informed consent, a total number of  
110 patients were assigned to the study, having the inclusion cri-
teria: ASA score I-II, age 30-80 years, Body Mass Index (BMI) 
20-30, Hct ≥ 30 % and indication of  primary TKA.
Patients were not eligible for the study if  they had history of  
bleeding disorders, peptic ulcer or gastrointestinal bleeding, se-
vere liver and kidney dysfunction, bronchial asthma, congestive 
heart failure (NYHA II-IV), neuropathies, allergies to the drugs 
used in the study, psychiatric disorders, chronic treatment with 
corticosteroids or long-acting NSAIDs administered in the last 
4 days preoperatively, as well as those with cerebrovascular or 
peripheral arterial disease or arterial hypertension not adequately 
controlled.
Patients who met the criteria were enrolled and randomized by a 
computer generated random number list (http://www.graphpad.
com/quickcalcs), conducted by an investigator who was not in-
volved in this study. The result placed inside a numbered envelope 
(one number corresponding to one patient of  the study). Anoth-
er investigator also not involved in treating patients opened the 
sealed envelope and administered the pills, according to patient’s 
allocation group:
- LORNOXICAM group with 55 patients who received one pill 
of  8 mg PO at the end of  surgery, immediately after arrival in the 
postoperative care unit (PACU) and a second pill after 12 hours.
- ETORICOX group with 55 patients who received a pill of  120 
mg PO at the end of  surgery, also immediately after arrival in 
PACU and a second placebo pill after 12 hours.
Before initiation of  the neuraxial block, patients received into the 
pre-anesthesia area a sodium chloride 0.9% infusion at a rate of  
250 ml h-1 containing the antibiotic for surgical prophylaxis on a 
16-gauge peripheral vein catheter (Vasofix® BBraun, Melsungen, 
Germany). All patients were premedicated with 0.03 mg/kg IV 
Midazolam (Dormicum®, Roche, Switzerland). Spinal anesthesia 
was performed with 0.5% isobaric plain bupivacaine 0.3 mg/kg 
using 25 or 27 pencil-point gauge Whitacre needles, the spinal 
puncture taking place in the sitting position at the L3-L4 interver-
tebral space.
At 15-20 minutes after the injection of  the local anesthetic, mo-
tor block was assessed by Bromage scale and sensory block level 
was tested by loss of  sensation to pinprick. Intraoperative seda-
tion was provided with boluses of  IV 10-20 mg of  propofol to 
maintain a 3 sedation level on a Ramsay scale [13]. Electrocardio-
gram in D2 and V5 leads, peripheral oxygen saturation (SpO2) 
and non-invasive blood pressure automatically every 5 minutes 
were monitored by Draeger (Draeger Medical Systems Monitor, 
Draeger AG, Luebeck, Germany) during the surgery ; the urinary 
output was recorded orally. Also the body temperature (axillar) 
was maintained at 36.5°C by an electric warming blanket (Bair-
Hugger®). Oxygen was administered at 5-6 L min-1 by a facemask.
At the end of  the surgery the patients were taken to the PACU 
for the next 48 h where they were monitored as intraoperative. 
The pills were administrated according to randomization. During 
the postoperative period, the patients were asked to quantify their 
pain using the numerical rating scale (NRS, from 0 - no pain - to 
10 -the most pain possible).
The multimodal analgesia plan was started when NRS > 3 with 
the administration of  paracetamol (Perfalgan®, Bristol- Myers - 
Squibb, New York, USA) 1g IV in 15 minutes every 8 hours for 
the next 48 hours followed by administration of  morphine (Mor-
phine hydrochloride®, Sanofi Aventis Zentiva, Paris, France) if  
NRS persists to remain above 3, with a loading bolus of  0.1 mg/
kg IV supplemented with 2 mg IV every 5 minutes until NRS < 
3 according to the IV titration protocol approved and applied in 
PACU of  our hospital. This analgesia protocol was applied until 
48 hours from end of  surgery. Ondansetron 4 mg IV was ad-
ministered before the first dose of  morphine to all patients (Os-
etron®, Dr. Reddy 's, India).
Adverse effects such as respiratory depression, nausea, vomiting, 
sedation, bradycardia, dizziness, urinary retention after removal 
of  the catheter, pruritus or desaturation were recorded through-
out the study. Sedation was evaluated by Ramsay scale. Respira-
tory depression was considered at a breathing rate ≤ 8/min and 
treated with naloxone. In case of  SPO2 ≤ 95%, oxygen was given 
on a facemask. Heart rate < 50/min was considered as brady-
cardia and treated with IV atropine 10 μg/kg. Hypotension was 
defined as MAP < 70 mmHg and treated with IV ephedrine 5-10 
mg IV and saline solution.
The following outcome parameters were monitored during the 
study:
a. Primary outcome: The cumulative morphine (mg) consumed 
during the first 24 hours and 48 hours postoperatively to maintain 
NRS ≤ 3, at rest;
b. Secondary outcomes:
b.1. The duration of  analgesia defined as the time from the ini-
tiation of  spinal anesthesia until the first analgesic requirement 
(min);
b.2. The side effects of  the treatment for 48 hours.
All parameters were evaluated by medical staff  not aware of  the 
patients randomization.
The statistical analysis was performed using GraphPad Prism 6.0 
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(GraphPad Software, Inc, La Jolla CA 92037, USA).
For an alpha type (false positive) error rate of  0.05 % and a beta 
type (false negative) error rate of  90% , assuming a mean value of  
morphine consumption of  40 mg ± 20 mg (SD) in the etoricoxib 
group (14.15), and a reduction with 30% of  this value in the lor-
noxicam group, the sample size needed was 58 patients in each of  
the two groups. (http://clincalc.com/Stats/SampleSize).
Continuous variables ( age, BMI, quantity of  morphine used, du-
ration of  analgesia) are presented as means ± SD when distri-
bution was found normal, or median ± 25-75% quartiles when 
distribution was nonsymmetric. The two groups were compared 
using Mann-Whitney test. Nominal data (gender, side effects) are 
presented as frequency tables and compared using Fisher’s exact 
test. A value of  p < 0.05 was considered statistically significant.
Results
In the period september 2014 - april 2015 out of  the 124 patients 
meeting the inclusion criteria, a number of  14 were excluded be-
cause of  requesting another type of  anesthesia or refusal to sign 
informed consent. The groups were similar in terms of  ASA class, 
age, BMI, gender, number of  patients, surgery type and duration, 
data being presented as mean ± standard deviationin Table 1.
At 24 hours after surgery no statistically significant difference was 
noted between groups regarding the morphine consumption, 36.2 
± 12 mg in Lornoxicam group, and respectively 34.5 ± 14.1 mg in 
Etoricoxib group; also, at 48 hours postoperatively the morphine 
administered was 15.6 ± 12.8 mg in Lornoxicam group and 18 ± 
12.3 mg in Etoricoxib group, with no significant difference be-
tween groups (p = 0.265 and 0.326 respectively).
The duration of  analgesia was not different between the 2 groups: 
314.5 ± 70.4 min in Lornoxicam group and 320.4 ± 89.2 min in 
Etoricoxib group (P = 0.708), the results being presented as mean 
± standard deviation in Table 2.
The overall incidence of  adverse events in the 2 groups during the 
first 48 hours is shown in Table 3. The tolerability of  etoricoxib 
appeared to be superior to lornoxicam, with less number of  pa-
tients experiencing adverse drug reactions. 
Discussion
The results of  the present study showed no significant difference 
regarding the duration of  analgesia and morphine consumption at 
24 and 48 hours postoperatively after TKA when lornoxicam or 
etoricoxib were administered at the end of  surgery, immediately 
after the patients arrived in the PACU. Lomoxicam was well toler-
ated in this study and although fewer patients experienced adverse 
effects in Etoricoxib group, the differences are not statistically 
significant.
Clinical trials that evaluate the effectiveness and safety of  lornoxi-
cam as part of  a multimodal analgesic regimen in reducing post-
operative pain and decreasing the need for rescue medications 
in orthopaedic and other types of  surgery are becoming more 
numerous [14-16]. 
The general precautions with regard to the use of  NSAIDs and 
the potential risks, like gastrointestinal bleeding, kidney problems 
and/or cardiovascular side effects must be acknowledged.
Table 1. Demographic Data (Mean ± SD).
Etoricoxib Group Lornoxicam Group
Number 55 55
Age (year) 66.12 ± 8.5 64.2 ± 7.3
BMI 29 ± 2 29 ± 7
Sex (F/M) 44/11 45/10
Duration of  surgery 123 ± 20 122 ± 22
Table 2. Morphine Requirements (Mean ± SD) and Time Lasting Analgesia (Mean ± SD).
Morphine Requirements (mg) Etoricoxib Group Lornoxicam Group P value
Surgery day 34.5 ± 14.1 36.2 ± 12 NS
Day one 18 ± 12.3 15.6 ± 12.8 NS
Lasting analgesia (min) 320.4 ± 89.2 314.5 ± 70.4 NS
Table 3. The Number and Percentage of  Patients with Side Effects.
Etoricoxib Group Lornoxicam Group P value
Nausea 2/55 (1.1%) 4/55 (2.2%) NS
Vomiting 1/55 (0.5%) 3/55 (1.6%) NS
Sedation 1/55 (0.5%) 1/55 (0.5%) NS
Bradycardia 2/55 (1.1%) 2/55 (1.1%) NS
Dizziness 0/55 0/55 NS
Urinary retention 0/55 0/55 NS
Pruritus 0/55 1/55 (0.5%) NS
Desaturation 0/55 0/55 NS
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In a randomized, placebo controlled study conducted by Inan et 
al., lornoxicam in a dose of  24 mg in the surgery day and 8 mg 
for the next 24 hours reduced morphine consumption and side 
effects related to morphine without additional side effects of  lor-
noxicam after total knee replacement [17].
Sivrikoz et al., reported an improved analgesia and a decreased 
morphine consumption following hip and knee arthroplasty after 
IV postoperative administration of  lornoxicam 8 mg twice a day 
or dexketoprofen 50 mg twice a day [18].
The introduction of  selective inhibitors of  COX-2 has provided 
new options in the postoperative pain management of  patients 
because coxibs are not associated with most of  the side effects 
of  NSAIDs like platelet dysfunction and stomach problems.In a 
study published in 2013 Lin et col. have shown the advantages of  
perioperative administration of  COX-2 inhibitors [19].
Studies comparing non-selective with selective NSAIDs to treat 
acute postoperative pain are rare [20]. White et al., conducted a 
randomized controlled study to evaluatethe effects of  postopera-
tive administration of  a nonselective nonsteroidal anti-inflamma-
tory drug, ibuprofen, in a dose of  1200 mg/day versus celecoxib, 
a cyclooxygenase-2 selective inhibitor,in a dose of  400 mg/day 
on the postoperative pain and the need for analgesics medication 
in ambulatory surgery. Both anti-inflammatory drugs significantly 
decreased the need for opioids in the early postdischarge period, 
leading to an improvement in the quality of  recovery and patient 
satisfaction [21].
In another prospective, randomized, double‐blinded, placebo‐
controlled study Papadima compared the efficacy of  lornoxicam 
versus parecoxib for the management of  pain after laparoscopic 
cholecystectomy on 76 patients and concluded that lornoxicam 
8 mg i.v. provided statistically equivalent pain relief  to that of  
parecoxib 40 mg i.v. and both were more efficacious than placebo 
[22].
Our prospective double-blinded randomized study investigated 
the postoperative analgetic efficacy of  lornoxicam versus etori-
coxib. To our knowledge this is the first study comparing lornoxi-
cam and etoricoxib in postoperative pain management.
We preferred to study etoricoxib because this drug has a rapid 
bioavailability via the oral route and the half-life longer than other 
coxibs could be an advantage by extending the analgetic effect. 
On the other hand, lornoxicam has a rapid onset of  action com-
pared to other oxicams, which it is also an important factor in the 
immediate postoperative period.
The present study has certain limitations because all parameters 
evaluated in the study were followed up for 48 hours only and no 
long-term data about pain, analgesic requirements or the safety 
of  the drug given perioperatively were given. Also, we evaluated 
the pain only at rest; thus, it remains uncertain whether the results 
would be similar during the rehabilitation methods and recovery.
Conclusion
Postoperative use of  lornoxicam for 48 hours in the dose of  8 mg 
PO twice a day is safe, effective and comparable to etoricoxib 120 
mg in postoperative pain relief  after TKA.
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